| Page 72 | Aplastic Anemia and MDS International Foundation (AAMDSIF)

Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria.

Author(s):

Griffin M, Hillmen P, Munir T, Richards S, Arnold L, Riley K, Hill A.

Primary Author:

Griffin M

Journal Title:

Haematologica

Original Publication Date:

Mar 2019

no abstract available

Bone Marrow Disease(s):

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry

Author(s):

Lee JW, Peffault de Latour R, Brodsky RA, Jang JH, Hill A, Röth A, Schrezenmeier H, Wilson A, Marantz JL, Maciejewski JP.

Primary Author:

Lee JW

Journal Title:

Am J Hematol

Original Publication Date:

Jan 2019

No abstract available

Bone Marrow Disease(s):

Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates

Author(s):

Dulau-Florea A, Maric I, Calvo KR, Braylan RC.

Primary Author:

Dulau-Florea A

Journal Title:

Semin Hematol

Original Publication Date:

Jan 2019

Bone Marrow Disease(s):

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Kat Edmonds knows patients, but more importantly, she coaches them on how to make the best decisions for their own lives. Find out more here:

Kat hears patients ask: "I have this bone marrow failure problem ... how is this going to affect me and loved ones? What does this mean for my life?" Discover how Kat helps walk patients through diagnosis, treatment, and survivorship.

Busy, happy retirement shaken by MDS - AML: Shirley's story of survivorship!

From a sunny, lively retirement to MDS then AML? That was Shirley's life! After treatment in a Clinical Trial, she is in remission, still playing the accordion! This is her story.

Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.

Author(s):

Cooper JP, Farah RJ, Stevenson PA, Gooley TA, Storb R, Scott BL.

Primary Author:

Cooper JP

Journal Title:

Biol Blood Marrow Transplant.

Original Publication Date:

Feb 2019

Bone Marrow Disease(s):

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Is sleep that important for bone marrow disease patients? Discover Dr. Mekonnen's insights here:

Can sleep affect your treatment for bone marrow failure diseases? Dr. Asefa Mekonnen explains why sleep is important for patients as well as when to tell your doctor that you aren't sleeping well. Check this out!

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Author(s):

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell P

Primary Author:

Haase D

Journal Title:

Leukemia

Original Publication Date:

Jan 2019

Risk stratification is critical in the care of patients with

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.

Author(s):

Zeidan AM, Klink AJ, McGuire M, Feinberg B.

Primary Author:

Zeidan AM

Journal Title:

Leuk Lymphoma.

Original Publication Date:

Jan 2019

Lenalidomide and hypomethylating agents (HMAs) azacitidine and decitabine are approved for treating

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Calculator-free point-of-care prognostication in myelodysplastic syndromes.

Author(s):

Tefferi A, Hanson CA, Ketterling RP, Pardanani A, Gangat N.

Primary Author:

Tefferi A

Journal Title:

Am J Hematol

Original Publication Date:

Jan 2019

No abstract available

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)